GLENMARK PHARMACEUTICALS
Back to Balance Sheet
|
GLENMARK PHARMACEUTICALS Last 5 Year Contingent Liabilities History
[Consolidated]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 | |
|---|---|---|---|---|---|
| Contingent Liabilities | ₹800 Cr | ₹1,063 Cr | ₹337 Cr | ₹361 Cr | ₹384 Cr |
What is the latest Contingent Liabilities ratio of GLENMARK PHARMACEUTICALS ?
| Year | Contingent Liabilities |
|---|---|
| Mar2025 | ₹800 Cr |
| Mar2024 | ₹1,063 Cr |
| Mar2023 | ₹337 Cr |
| Mar2022 | ₹361 Cr |
| Mar2021 | ₹384 Cr |
How is Contingent Liabilities of GLENMARK PHARMACEUTICALS Trending?
| Years | Contingent Liabilities | % Change | |
|---|---|---|---|
| Mar2025 | ₹800 Cr | -24.74 | |
| Mar2024 | ₹1,063 Cr | 215.81 | |
| Mar2023 | ₹337 Cr | -6.81 | |
| Mar2022 | ₹361 Cr | -5.96 | |
| Mar2021 | ₹384 Cr | - | |
Compare Contingent Liabilities of peers of GLENMARK PHARMACEUTICALS
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| GLENMARK PHARMACEUTICALS | ₹56,456.9 Cr | -0.3% | 1.8% | 34.3% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹400,497.0 Cr | -3.5% | -6.4% | -2.6% | Stock Analytics | |
| DIVIS LABORATORIES | ₹165,492.0 Cr | -5.8% | -1.6% | 10.9% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹136,013.0 Cr | 1.4% | 7% | 23.7% | Stock Analytics | |
| CIPLA | ₹112,922.0 Cr | -4.7% | -6.8% | -0.3% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹98,115.0 Cr | -2.8% | -8.1% | -11.1% | Stock Analytics | |
GLENMARK PHARMACEUTICALS Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| GLENMARK PHARMACEUTICALS | -0.3% |
1.8% |
34.3% |
| SENSEX | -0.7% |
-1.9% |
8% |
You may also like the below Video Courses